Extrait

Primary study objective is to assess the effect of quetiapine XR with or without concomitant participation in the ICP on the subjective well-being in patients treated for symptomatic schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder or psychotic disorder not otherwise specified, measured by the patients' self-report instrument SWN-K total score with a result of ≥ 80 defined as the response limit for an adequate subjective well-being over a study treatment period of 18 months.

Critère d'inclusion

• Symptomatic schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder or psychotic disorder not otherwise specified

Liens

• ictrp
• euctr